"First 10 Drugs Chosen for Medicare Price Negotiation by Biden-Harris Administration"

The Biden-Harris Administration has announced the first ten drugs selected for Medicare price negotiation, marking a significant milestone in their efforts to lower healthcare and prescription drug costs. These drugs, which include treatments for conditions such as diabetes, heart failure, and cancer, have high total spending in Medicare Part D. Negotiations for these drugs will begin in 2023, with the aim of reducing out-of-pocket costs for seniors and saving money for taxpayers. The administration is also taking additional steps to lower prescription drug costs, including capping insulin prices at $35 per month and expanding negotiation authority for more drugs.